Healthcare Industry News: Cardima
News Release - October 23, 2007
Cardima Appoints Dr. Arjun Sharma as Chief Medical Officer
FREMONT, CA--(Healthcare Sales & Marketing Network)--Oct 23, 2007 -- Cardima, Inc. (OTC BB:CADM.OB ), developer of the REVELATION® Tx, REVELATION® T-Flex ablation microcatheters and INTELLITEMP® Energy Management Device, announces today that Arjun D. Sharma, M.D., F.A.C.C., has joined the Company as Chief Medical Officer. Dr. Sharma is a trained cardiologist and cardiac electrophysiologist.In commenting on Dr. Sharma's appointment, Cardima's Chairman, Mr. Shum, said, "Dr. Sharma is an extremely talented and experienced electrophysiologist who will make a significant contribution to our team of professionals. Dr. Sharma is a physician of international reputation who has published extensively and lectured internationally."
Dr. Sharma's career has included both clinical and academic achievements. He has participated in over 50 clinical trials, including many of the most important and clinically relevant trials in the area of cardiology and rhythm management. Dr. Sharma has contributed extensively to leading edge academic research in the field of cardiology. He has also served as a scientific adviser to major pharmaceutical and medical device manufacturers in areas mostly related to advances in cardiac treatments.
Dr. Sharma has experience using Cardima's ablation systems as part of the Company's clinical trials, as well as the mapping and guide catheter product lines.
The entire Board of Directors welcomes Dr. Sharma's appointment.
About Cardima
Cardima, Inc. has developed the PATHFINDER® Series of diagnostic catheters, the REVELATION® Series of ablation catheters, the INTELLITEMP® Energy Management Device, and the Surgical Ablation System (SAS). The REVELATION® Series with the INTELLITEMP® Energy Management Device was developed for the treatment of atrial fibrillation (AF) and received CE mark approval in Europe. The PATHFINDER® Series diagnostic catheters and the SAS with an INTELLITEMP® received FDA 510(k) clearance in the U.S.
For more information, please visit the Company's website at http://www.Cardima.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward-looking statements. Potential risks and uncertainties include: the uncertainties associated with the prospects for FDA approval of any new devices; the prospect for any future clinical trials or regulatory activities; the risk that the Company will not be able to raise additional capital in the immediate term as needed to continue operations and the risk that we will be unable to secure a strategic transaction involving the Surgical Ablation System. Additional risks and uncertainties are set forth in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the second quarter ended June 30, 2007, and in the Company's subsequent SEC filings. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.
Source: Cardima
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
